HbA1c ReductionFreestyle Libre 1 FGM use

Clinical evidence dossier

Freestyle Libre 1 FGM use

HbA1c

Evidence signal

Evidence signal

Strong

This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.

Evidence snapshot

Authoritative support records
3
Supporting studies available for review
3
Randomized trials
3
Reported effects
7

Clinical conclusion

Freestyle Libre 1 FGM use has a small positive evidence signal for HbA1c, but the clinical interpretation is limited.

The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.

Observed effects

Observed study estimates; not a pooled treatment effect.

Change from baseline

Absolute change

−0.7% to 0%

5 eligible estimates12–12 weeksObserved median: −0.3%

Change from baseline

Mean difference

−0.44% to −0.44%

1 eligible estimates12–12 weeksObserved median: −0.44%

Between-group effect

Mean difference

0.1% to 0.1%

1 eligible estimates4–4 weeksObserved median: 0.1%

Evidence composition

Non-randomized studies
0
Other designs
0
Unresolved designs
0
Magnitude-eligible effects
7

Consistency

Consistency classification

Consistent

Positive
0
No effect
2
Mixed
1
Negative
0

Population and applicability

Structured population data were available for 3 of 3 supporting studies. Diabetes type was heterogeneous: 1 studies with type 1 diabetes, 1 studies with type 2 diabetes. 1 study described adult participants.

This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.

View reported population descriptions

These descriptions are reported across the supporting studies; they are not a single synthesized population.

  • Pregnant women diagnosed with gestational diabetes mellitus.
  • Participants requiring blood glucose monitoring during pregnancy.
  • Participants residing in India.
  • Indigenous Australians with type 2 diabetes.
  • Adults aged 18 and older with diabetes management needs.

Limitations

  • 1 supporting study does not have a displayable topic-matched quantitative effect.
  • Evidence uses heterogeneous comparison contexts: active_comparator, usual_care.

Supporting evidence

Inspect the authoritative studies and omitted support records for this dossier.

View supporting evidence